GlassScriptPhysician profile
Scott Chadwick Evans
NPI 1366464836
$13,347.75
in general payments reported to CMS, 2019-2025
63 companies · $1,454 in 2025
The $1,454 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,630 · 2020: $1,741 · 2021: $2,320 · 2022: $1,995 · 2023: $1,816 · 2024: $2,392 · 2025: $1,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,647 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,647.07 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,387.55 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,117.36 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Abbvie INC. | $1,044.14 | 2021-2025 | |
| Amgen INC. | $947.56 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $815.69 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $686.52 | 2019-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $628.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $524.51 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $501.96 | 2019-2022 | |
| Glaxosmithkline, LLC. | $446.65 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $365.77 | 2019-2025 | Xifaxan |
| Eisai INC. | $316.85 | 2020-2024 | |
| Exact Sciences Corporation | $302.48 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $291.26 | 2024-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $276.65 | 2019-2023 | Xarelto |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.